Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
Andrew J PalmerTing ZhaoBruce V TaylorIngrid A van der MeiJulie A CampbellPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
MS prevention using future EBV vaccinations, particularly targeted at adolescence population, is highly likely to be cost-effective.